Terms: = Prostate cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Treatment
220 results:
1. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant prostate cancer.
Turnham DJ; Mullen MS; Bullock NP; Gilroy KL; Richards AE; Patel R; Quintela M; Meniel VS; Seaton G; Kynaston H; Clarkson RWE; Phesse TJ; Nelson PS; Haffner MC; Staffurth JN; Pearson HB
Cells; 2024 Apr; 13(8):. PubMed ID: 38667288
[TBL] [Abstract] [Full Text] [Related]
2. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
3. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
4. Curcumin Enhances the Anti-cancer Efficacy of CDK4/6 Inhibitors in prostate cancer.
Zhao H; Ding R; Han J
Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
[TBL] [Abstract] [Full Text] [Related]
5. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
6. Combined Cabazitaxel and Carboplatin treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
7. treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
8. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
[TBL] [Abstract] [Full Text] [Related]
9. Drastic Synergy of Lovastatin and
Yao CJ; Chang CL; Hu MH; Liao CH; Lai GM; Chiou TJ; Ho HL; Kuo HC; Yang YY; Whang-Peng J; Chuang SE
Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960146
[TBL] [Abstract] [Full Text] [Related]
10. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
11. Ultrasound targeted microbubble destruction using docetaxel and Rose Bengal loaded Microbubbles for targeted Chemo-Sonodynamic therapy treatment of prostate cancer.
McKaig T; Logan K; Nesbitt H; Callan B; McKeown S; O'Sullivan JM; Kelly P; O'Rourke D; McHale AP; Callan JF
Eur J Pharm Biopharm; 2023 Nov; 192():196-205. PubMed ID: 37858804
[TBL] [Abstract] [Full Text] [Related]
12. Photodynamic treatment of Human Breast and prostate cancer Cells Using Rose Bengal-Encapsulated Nanoparticles.
Uddin MMN; Bekmukhametova A; Antony A; Barman SK; Houang J; Wu MJ; Hook J; George L; Wuhrer R; Mawad D; Ta D; Lauto A
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836744
[TBL] [Abstract] [Full Text] [Related]
13. Light-responsive smart nanocarriers for wirelessly controlled photodynamic therapy for prostate cancers.
Sun B; Liu J; Kim HJ; Rahmat JNB; Neoh KG; Zhang Y
Acta Biomater; 2023 Nov; 171():553-564. PubMed ID: 37739246
[TBL] [Abstract] [Full Text] [Related]
14. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.
Agarwal S; Fang L; McGowen K; Yin J; Bowman J; Ku AT; Alilin AN; Corey E; Roudier MP; True LD; Dumpit R; Coleman I; Lee JK; Nelson PS; Capaldo BJ; Mariani A; Hoover C; Senatorov IS; Beshiri M; Sowalsky AG; Hurt EM; Kelly K
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37725435
[TBL] [Abstract] [Full Text] [Related]
15. Genomic Evolution and Transcriptional Changes in the Evolution of prostate cancer into Neuroendocrine and Ductal Carcinoma Types.
Rao SR; Protheroe A; Cerundolo L; Maldonado-Perez D; Browning L; Lamb AD; Bryant RJ; Mills IG; Woodcock DJ; Hamdy FC; Tomlinson IPM; Verrill C
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628903
[TBL] [Abstract] [Full Text] [Related]
16. Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the treatment of Metastatic Castration-Resistant prostate cancer.
Slovin SF; Knudsen K; Halabi S; de Leeuw R; Shafi A; Kang P; Wolf S; Luo B; Gopalan A; Curley T; Fleming M; Molina A; Fernandez C; Kelly K
J Clin Oncol; 2023 Nov; 41(32):5015-5024. PubMed ID: 37582240
[TBL] [Abstract] [Full Text] [Related]
17. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
[TBL] [Abstract] [Full Text] [Related]
18. Case Series of Men with the Germline APC I1307K variant and treatment-Emergent Neuroendocrine prostate cancer.
Economides MP; Nakazawa M; Lee JW; Li X; Hollifield L; Chambers R; Sarfaty M; Goldberg JD; Antonarakis ES; Wise DR
Clin Genitourin Cancer; 2024 Feb; 22(1):e31-e37.e1. PubMed ID: 37482523
[TBL] [Abstract] [Full Text] [Related]
19. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract] [Full Text] [Related]
20. Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
Nyquist MD; Coleman IM; Lucas JM; Li D; Hanratty B; Meade H; Mostaghel EA; Plymate SR; Corey E; Haffner MC; Nelson PS
Cancer Res; 2023 Sep; 83(17):2938-2951. PubMed ID: 37352376
[TBL] [Abstract] [Full Text] [Related]
[Next]